share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股SEC公告 ·  08/23 16:13
Moomoo AI 已提取核心信息
bluebird bio, Inc., a biotechnology company listed on Nasdaq under the ticker symbol BLUE, is facing compliance issues due to delayed financial filings. The company has not filed its Annual Report for 2023 or its Quarterly Reports for Q1 and Q2 of 2024, which has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires timely submission of periodic financial reports. bluebird bio received notification letters from Nasdaq on August 20, 2024, regarding this non-compliance. The company had previously reported the need to restate its consolidated financial statements for 2022 and the first three quarters of 2023, which has contributed to the delay. Nasdaq has granted bluebird bio a compliance period until October 14, 2024, to file the overdue reports and regain compliance. The company plans to...Show More
bluebird bio, Inc., a biotechnology company listed on Nasdaq under the ticker symbol BLUE, is facing compliance issues due to delayed financial filings. The company has not filed its Annual Report for 2023 or its Quarterly Reports for Q1 and Q2 of 2024, which has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires timely submission of periodic financial reports. bluebird bio received notification letters from Nasdaq on August 20, 2024, regarding this non-compliance. The company had previously reported the need to restate its consolidated financial statements for 2022 and the first three quarters of 2023, which has contributed to the delay. Nasdaq has granted bluebird bio a compliance period until October 14, 2024, to file the overdue reports and regain compliance. The company plans to update its Compliance Plan by September 4, 2024, and intends to file the necessary reports as soon as possible. Despite the notices, there is no immediate impact on the trading of bluebird bio's securities on Nasdaq. The company has issued a press release on August 23, 2024, to publicly announce the receipt of the Nasdaq notices.
生物技术公司bluebird bio, Inc.在纳斯达克上市,股票代码为BLUE,由于延迟提交财务报告而面临合规问题。该公司尚未提交2023年年度报告或2024年第一和第二季度的季度报告,这导致未能符合纳斯达克5250(c)(1)上市规则。该规则要求定期财务报告的及时提交。bluebird bio公司于2024年8月20日收到纳斯达克关于此违规行为的通知函。该公司此前曾报告需要重述其2022年和2023年前三个季度的合并财务报表,这也导致了延迟。纳斯达克已经向bluebird bio公司授予了合规期限,直到2024年10月14日提交逾期报告并恢复合规。该公司计划在2024年9月4日前更新其合规计划,并打算尽快提交必要的报告。尽管收到通知,但对纳斯达克上bluebird bio证券的交易没有立即影响。该公司已于2024年8月23日发布新闻稿公开宣布收到纳斯达克通知。
生物技术公司bluebird bio, Inc.在纳斯达克上市,股票代码为BLUE,由于延迟提交财务报告而面临合规问题。该公司尚未提交2023年年度报告或2024年第一和第二季度的季度报告,这导致未能符合纳斯达克5250(c)(1)上市规则。该规则要求定期财务报告的及时提交。bluebird bio公司于2024年8月20日收到纳斯达克关于此违规行为的通知函。该公司此前曾报告需要重述其2022年和2023年前三个季度的合并财务报表,这也导致了延迟。纳斯达克已经向bluebird bio公司授予了合规期限,直到2024年10月14日提交逾期报告并恢复合规。该公司计划在2024年9月4日前更新其合规计划,并打算尽快提交必要的报告。尽管收到通知,但对纳斯达克上bluebird bio证券的交易没有立即影响。该公司已于2024年8月23日发布新闻稿公开宣布收到纳斯达克通知。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息